Avantis Medical Systems said it brought in $4.8 million of a hoped-for $10.6 million debt round.

Sunnyvale, Calif.-based Avantis makes catheter-based endoscopic devices designed to detect and treat and gastrointestinal cancers, according to its website. It’s flagship product is the Third Eye "retrospect" for colonoscopies.

Unlike standard endoscopes, the Third Eye device has a 2nd camera it uses to create a "retrograde view" of the interior of the colon, to allow physicians to see polyps that might otherwise have been hidden in the organs folds, according to the website.

Avantis touts a clinical study showing a 23% increase in the net adenoma detection rate and another showing a 40% detection increase in high-risk patients.

Six unnamed investors have participated in the funding round so far, according to a regulatory filing.